Alnylam Pharmaceuticals funds independent educational initiatives advancing medical knowledge in rare diseases like ATTR amyloidosis, AHP, and PH1 through RFP-based grants.
Alnylam Pharmaceuticals’ Educational Grants fund independent educational projects advancing clinical knowledge in ATTR amyloidosis, AHP, and PH1.
Alnylam Pharmaceuticals' CME Grants fund independent, evidence-based education for healthcare professionals on ATTR amyloidosis, AHP, and PH1.
Independent Medical and Patient Education/Advocacy Grants support organizations’ medical education and patient education or advocacy initiatives to advance knowledge, improve care, and address community needs.
Novartis Office of Grants & Education Request for Proposal (RFP) - Professional Medical Education supports US clinicians with independent education on DMD, DM1, and FSHD to improve patient care.